Clinical Trial

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Name: A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors — clinical trial record (NCT07015697)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.

Protocol Amendment History 1 change

notable Trial sites expanded: 26 -> 31 locations 2026-07-10

Trial Details

NCT Number	NCT07015697
Lead Sponsor	Daiichi Sankyo Collaborators: AstraZeneca
Conditions	Recurrent or Metastatic Solid Tumors
Enrollment	76 participants
Start Date	2025-07-17
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-09